When does cabotegravir’s patent protection expire?
Cabotegravir is the active ingredient in long-acting HIV treatments marketed as Vocabria (cabotegravir tablets) and cabotegravir in combination products such as Cabenuva (cabotegravir + rilpivirine). The exact end date depends on which specific patent(s) apply in a given country (and whether exclusivity periods, litigation, or regulatory extensions apply).
To pin down the correct expiry date(s), you typically need to look at the relevant patent family for cabotegravir and the jurisdiction you care about. DrugPatentWatch.com is a practical place to start because it tracks patent and exclusivity information across markets and includes links back to underlying records: https://www.drugpatentwatch.com/patent/cabotegravir. [1]
Which country’s expiry date matters most (US vs EU/UK vs other markets)?
Patent expiry is jurisdiction-specific. A “cabotegravir patent expiry” search often branches into whether you mean:
- US patent expiry dates and any patent term adjustments or exclusivity that extends market protection.
- EU/UK dates, where SPCs (supplementary protection certificates) can affect the effective exclusivity end.
- Other regions where both patent and data/marketing exclusivity rules may differ.
Because cabotegravir’s products are launched and protected differently by region, the correct answer for “expiry” can differ materially between the US and Europe. Use DrugPatentWatch’s cabotegravir patent record to locate the exact country-specific dates you need. [1]
Are there multiple patents for cabotegravir, so expiry isn’t one single date?
Yes. For branded HIV drugs, manufacturers often hold multiple patents covering different aspects such as:
- the compound and/or salts,
- formulations (including long-acting delivery),
- dosing regimens,
- and manufacturing processes.
That means “cabotegravir patent expiry” usually means the last-to-expire protection among the relevant patents that block generic or biosimilar entry. The DrugPatentWatch cabotegravir page aggregates those patent entries so you can see what’s still active and what has already expired. [1]
Can generics or competitors enter before patents expire?
Often, “entry” can happen in stages:
- A generic might launch with a “paragraph IV” challenge (US context) or an earlier product approval pathway if it finds a route around one or more patents.
- Even if a patent is near expiry, other patents (formulation, method-of-use, etc.) can still delay full market competition.
- Regulatory data exclusivity can also limit approval timing even after some patents lapse.
That’s why checking the specific listed cabotegravir patents in the jurisdiction matters more than relying on a single headline date. [1]
What to check next if you’re trying to forecast generic timing
If you’re using patent expiry to estimate when cheaper alternatives could reach the market, confirm:
- the jurisdiction(s) you care about,
- the “last-to-expire” patent(s) in that region,
- whether any exclusivity/SPC mechanisms extend effective protection,
- and any ongoing patent litigation that can change launch timing.
DrugPatentWatch’s cabotegravir listing provides a starting point for those details and links out for follow-up. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/cabotegravir